Italian scholar Sergio Bracarda published a randomized controlled study of sorafenib combined with interferon for advanced kidney cancer in the European Journal of Urology in 2012. Sorafenib has been shown to be effective in metastatic kidney cancer, while interferon has an anti-angiogenic effect, and this effect correlates with the dose and duration of administration. The objective of this study was to compare the efficacy of two interferon dosing regimens in combination with sorafenib in metastatic renal tumors. The study was characterized as a prospective, randomized, non-blinded, multicenter, phase 2 clinical study. The study population consisted of 101 patients with untreated metastatic kidney cancer. Patients in group A received sorafenib 400 mg twice daily combined with subcutaneous interferon 9 million units three times a week, and patients in group B received sorafenib 400 mg twice daily combined with interferon 3 million units subcutaneously five times a week. The primary study endpoint was time to progression-free survival, with a median progression-free survival of 7.9 months and 8.6 months (P=0.049) and a median time to response of 8.5 months and 19.2 months (P=0.0013) in groups A and B, respectively, which were significantly different. 9 partial responses in group A and 3 complete responses and 14 partial responses in group B (17.6% vs. 34.0%, P= 0.058); 24 and 21 patients in the two groups had stable disease (47% and 42%), respectively). The most common grade 3-4 adverse drug reactions were malaise and weakness (28% vs 16%, P=0.32) and hand, foot and mouth disease (20% vs 18%), with no significant differences between the two groups. This study confirms that sorafenib in combination with frequent low-dose interferon therapy showed good efficacy and tolerability, especially with a complete response rate of 6%, but further confirmation is needed in a large sample.